var data={"title":"Morphine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Morphine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390076?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">see &quot;Morphine: Drug information&quot;</a> and <a href=\"topic.htm?path=morphine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Morphine: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50711535\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Opioid Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada, in collaboration with manufacturers, will update the Canadian labelling of all prescription opioid products to include the following:</p>\n        <ul>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation for a daily opioid threshold dose for the management of chronic noncancer, nonpalliative pain (which aims to reduce risks of adverse events and overdoses associated with higher doses of opioids);</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation to limit the quantity of opioids prescribed for acute pain (which aims to reduce the duration of use and associated risks of developing dependence and substance use disorder); and</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Clarification of warnings, including those for special populations such as pregnant women and patients with a history of dependence or substance use disorder.</p></li></ul>\n        <p style=\"text-indent:0em;\">Health Canada has prioritized product tables for updating based on risk. The labelling updates for all prescription opioids are expected to be completed in January 2019.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65362a-eng.php.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">FDA Extends Expiration Dates for Certain Meridian Autoinjectors: Updated</span>\n      <span class=\"collapsible-date\">July 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA is alerting health care providers and emergency responders that certain lots of <i>AtroPen</i> (atropine), <i>CANA</i> (diazepam), morphine sulfate, and pralidoxime chloride autoinjectors manufactured by Meridian Medical Technologies can be used beyond the labeled expiration date, which should help mitigate potential shortages of these drugs. To ensure patient safety, products should be stored under the manufacturer&rsquo;s labeled storage conditions.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Additional information may be found at <a target=\"_blank\" href=\"http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm&amp;token=SHauxSdf9qNc6lLK16E8IDV3KxAgJ9eAUWFzIj8OhB+DS1QnG3nll2ktzEV1bFFqNvp/S6dk6auUFKQXeUZdHA==&amp;TOPIC_ID=16024\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775511\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks with neuroaxial administration (Infumorph, Duramorph):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the risk of severe adverse effects when the epidural or intrathecal route of administration is employed, patients must be observed in a fully equipped and staffed environment for at least 24 hours after the initial dose. Single-dose Duramorph neuraxial administration may result in acute or delayed respiratory depression for up to 24 hours. Monitor patients receiving Infumorph, as appropriate, for the first several days after catheter implantation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Ethanol use (extended-release capsules):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Instruct patients not to consume alcoholic beverages or use prescription or nonprescription products that contain alcohol while taking morphine extended-release (ER) capsules. The coingestion of alcohol with morphine ER may result in increased plasma levels and a potentially fatal overdose of morphine.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Addiction, abuse, and misuse:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Morphine exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing morphine and monitor all patients regularly for the development of these behaviors and conditions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Life-threatening respiratory depression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious, life-threatening, or fatal respiratory depression may occur with use of morphine. Monitor for respiratory depression, especially during initiation of morphine or following a dose increase. Swallow morphine ER formulations whole. ER capsule contents may be sprinkled on applesauce and swallowed immediately without chewing. Crushing, chewing, or dissolving the tablets or contents within the capsule can cause rapid release and absorption of a potentially fatal dose of morphine. Because of delay in maximum CNS effect with IV administration (30 minutes), rapid IV administration may result in overdosing. Observe patients in a fully equipped and staffed environment for at least 24 hours after each test dose of Infumorph and, as indicated, for the first several days after surgery.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neonatal opioid withdrawal syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prolonged use of morphine during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Accidental ingestion (oral formulations):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Accidental ingestion of even one dose of morphine, especially by children, can result in a fatal overdose of morphine.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of medication errors (oral solution):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ensure accuracy when prescribing, dispensing, and administering morphine oral solution. Dosing errors due to confusion between mg and mL, and other morphine solutions of different concentrations, can result in accidental overdose and death</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks from concomitant use with benzodiazepines or other CNS depressants:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of morphine and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776636\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Arymo ER;</li>\n      <li>AVINza [DSC];</li>\n      <li>Duramorph;</li>\n      <li>Infumorph 200;</li>\n      <li>Infumorph 500;</li>\n      <li>Kadian;</li>\n      <li>MorphaBond ER;</li>\n      <li>MS Contin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776637\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Doloral;</li>\n      <li>Kadian;</li>\n      <li>M-Eslon;</li>\n      <li>M.O.S. 10;</li>\n      <li>M.O.S. 20;</li>\n      <li>M.O.S. 30;</li>\n      <li>M.O.S.-SR;</li>\n      <li>M.O.S.-Sulfate;</li>\n      <li>Morphine Extra Forte Injection;</li>\n      <li>Morphine Forte Injection;</li>\n      <li>Morphine HP;</li>\n      <li>Morphine LP Epidural;</li>\n      <li>Morphine SR;</li>\n      <li>Morphine-EPD;</li>\n      <li>MS Contin;</li>\n      <li>MS Contin SRT;</li>\n      <li>MS-IR;</li>\n      <li>Novo-Morphine SR;</li>\n      <li>PMS-Morphine Sulfate SR;</li>\n      <li>ratio-Morphine;</li>\n      <li>ratio-Morphine SR;</li>\n      <li>Sandoz-Morphine SR;</li>\n      <li>Statex;</li>\n      <li>Teva-Morphine SR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10512349\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Analgesic, Narcotic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443893\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\"> <b>Doses should be titrated to appropriate effect;</b> when changing routes of administration in chronically treated patients, please note that oral doses are approximately one-half as effective as parenteral dose; <b>Note: Use preservative-free formulation: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Analgesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: 0.08 mg/kg/dose every 4 to 6 hours (APA 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM, IV (preferred), SubQ: Initial: 0.05 to 0.1 mg/kg/dose; usual frequency every 4 to 6 hours, although some neonates may require every 8 hour dosing; titrate carefully to effect; maximum dose: 0.1 mg/kg/dose (Anand 2001; Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous IV infusion: Initial: 0.01 mg/kg/<b>hour</b> (10 <b>mcg</b>/kg/<b>hour</b>); titrate carefully to effect; maximum: 0.03 mg/kg/<b>hour</b> (30 <b>mcg</b>/kg/<b>hour</b>) (Anand 2001); some have suggested a lower usual maximum infusion rate of 0.015 to 0.02 mg/kg/<b>hour</b> (15 to 20 <b>mcg</b>/kg/<b>hour</b>) due to decreased elimination, increased CNS sensitivity, and adverse effects; <b>Note:</b> Some centers may use slightly higher doses, especially in neonates who develop tolerance. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Endotracheal intubation, nonemergent:</b> IM, IV: 0.05 to 0.1 mg/kg; allow at least 5 minutes for onset of analgesia (Kumar 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Neonatal abstinence syndrome:</b> Limited data available: <b>Note:</b> The lowest concentration of the commercially available oral solution (2 mg/mL) should be utilized if possible; if doses are too small to accurately measure then a dilution of 0.4 mg/mL may be utilized (see Extemporaneous Preparation for dilution details). Oral: Initial: 0.04 mg/kg/dose every 3 to 4 hours; increase by 0.04 mg/kg/dose if symptoms are not controlled; maximum dose: 0.2 mg/kg/dose (Hudak 2012); dose and weaning schedule should be individualized based on signs and symptoms of withdrawal and/or withdrawal scores; once withdrawal symptoms are controlled, maintain dose for 48 to 72 hours; then taper dose usually by 10% to 20% every 2 to 7 days (Burgos 2009; Hudak 2012).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10512362\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">see &quot;Morphine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Doses should be titrated to appropriate effect;</b> use lower doses in opioid naive patients; when changing routes of administration in chronically treated patients, please note that oral doses are approximately one-half as effective as parenteral dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute pain, moderate to severe: Note:</b> Repeated SubQ administration causes local tissue irritation, pain, and induration. The use of IM injections is no longer recommended, especially for repeated administration due to painful administration, variable absorption, and lag time to peak effect; other routes are more reliable and less painful (American Pain Society 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &le;6 months, nonventilated: <b>Note:</b> Infants &lt;3 months of age are more susceptible to respiratory depression; lower doses are recommended (American Pain Society 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: Oral solution (2 mg/mL or 4 mg/mL): 0.08 to 0.1 mg/kg/dose every 3 to 4 hours (American Pain Society 2008; Berde 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV or SubQ: 0.025 to 0.03 mg/kg/dose every 2 to 4 hours (American Pain Society 2008; Berde 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &gt;6 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: Immediate release tablets, oral solution (2 mg/mL or 4 mg/mL):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &lt;50 kg: 0.2 to 0.5 mg/kg/dose every 3 to 4 hours as needed; some experts have recommended an initial dose of 0.3 mg/kg for severe pain; usual initial maximum dose: 15 to 20 mg (American Pain Society 2008; APA 2012; Berde 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &ge;50 kg: 15 to 20 mg every 3 to 4 hours as needed (American Pain Society 2008; Berde 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM, IV, or SubQ; intermittent dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &lt;50 kg: Opioid na&iuml;ve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose; higher doses may be required if pain not adequately controlled or if patient is opioid tolerant; usual range: 0.1 to 0.2 mg/kg/dose every 2 to 4 hours as needed; use lower doses in opioid na&iuml;ve patients; usual maximum dose: Infants: 2 mg/dose; Children 1 to 6 years: 4 mg/dose; Children 7 to 12 years: 8 mg/dose; Adolescents: 10 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &ge;50 kg: Initial: 2 to 5 mg every 2 to 4 hours as needed; Use lower end of the dosing range in opioid na&iuml;ve patients; higher doses have been recommended (5 to 8 mg every 2 to 4 hours as needed) and may be needed in tolerant patients (Berde 2002; Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous IV infusion, SubQ continuous infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &lt;50 kg: Initial: 0.01 mg/kg/hour (10 mcg/kg/hour); titrate carefully to effect; dosage range: 0.01 to 0.04 mg/kg/<b>hour</b> (10 to 40 <b>mcg</b>/kg/<b>hour</b>) (APA 2012; Friedrichsdorf 2007; Golianu 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patient weight &ge;50 kg: 1.5 mg/<b>hour</b> (Berde 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Conversion from intermittent IV morphine: Administer the patient's total daily IV morphine dose over 24 hours as a continuous infusion; titrate dose to appropriate effect</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Epidural:</b> Astramorph/PF, Duramorph: Limited data available: <b>Note:</b><b> Must use preservative-free formulation:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent: Infants, Children, and Adolescents: 0.015 to 0.05 mg/kg (15 to 50 <b>mcg</b>/kg) (APA 2012; Henneberg 1993); a trial evaluating pain relief in pediatric patients after abdominal surgery (n=76; age: Newborn to 13 years; median age: 12 months) administered epidural morphine every 8 hours in combination with bupivacaine during the immediate postop period; most children achieved good pain relief with this regimen (Henneberg 1993). Maximum dose: 0.1 mg/kg (100 <b>mcg</b>/kg) or 5 mg/24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous epidural infusion: Infants &gt;6 months, Children, and Adolescents: 0.001 to 0.005 mg/kg/<b>hour</b> (1 to 5 <b>mcg</b>/kg/<b>hour</b>) (Suresh 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Analgesia for minor procedures/sedation:</b> Infants, Children, and Adolescents: IV: 0.05 to 0.1 mg/kg/dose; administer 5 minutes before the procedure; maximum dose: 4 mg; may repeat dose in 5 minutes if necessary (Cramton 2012; Zeltzer 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Patient-controlled analgesia (PCA), opioid-na&iuml;ve: Note:</b> All patients should receive an initial loading dose of an analgesic (to attain adequate control of pain) before starting PCA for maintenance. Adjust doses, lockouts, and limits based on required loading dose, age, state of health, and presence of opioid tolerance. Use lower end of dosing range for opioid-na&iuml;ve. Assess patient and pain control at regular intervals and adjust settings if needed (American Pain Society 2008): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;5 years and Adolescents, weighing &lt;50 kg: <b>Note:</b> PCA has been used in children as young as 5 years of age; however, clinicians need to assess children 5 to 8 years of age to determine if they are able to use the PCA device correctly (American Pain Society 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Usual concentration: 1 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Demand dose: Usual initial: 0.02 mg/kg/dose; usual range: 0.01 to 0.03 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lockout: Usual initial: 5 doses/hour</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lockout interval: Range: 6 to 8 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Usual basal rate: 0 to 0.03 mg/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;5 years and Adolescents, weighing &ge;50 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Usual concentration: 1 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Demand dose: Usual initial: 1 mg; usual range: 0.5 to 2.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lockout interval: Usual initial: 6 minutes; usual range: 5 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic pain: Note:</b> Patients taking opioids chronically may become tolerant and require doses higher than the usual dosage range to maintain the desired effect. Tolerance can be managed by appropriate dose titration. There is no optimal or maximal dose for morphine in chronic pain. The appropriate dose is one that relieves pain throughout its dosing interval without causing unmanageable side effects. Consider total daily dose, potency, prior opioid use, degree of opioid experience and tolerance, conversion from previous opioid (including opioid formulation), patient's general condition, concurrent medications, and type and severity of pain during prescribing process.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Extended/controlled release preparations: A patient's morphine requirement should be established using immediate release formulations. Conversion to long acting products may be considered when chronic, continuous treatment is required. Higher dosages should be reserved for use only in opioid-tolerant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Capsules, extended release (Avinza):</i> Adolescents &ge;18 years: Daily dose administered once daily (for best results, administer at same time each day)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Opioid-naive: Initial: 30 mg once daily; adjust in increments &le;30 mg daily every 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Capsules, extended release (Kadian):</i> Adolescents &ge;18 years: <b>Note:</b> Not intended for use as an initial opioid in the management of pain; use immediate release formulations before initiation. Total daily oral morphine dose may be either administered once daily or in 2 divided doses daily (every 12 hours). The first dose of Kadian may be taken with the last dose of the immediate release morphine.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Tablets, controlled release (MS Contin):</i> Children and Adolescent able to swallow tablets whole: Usually not used as an initial opioid in the management of pain; use immediate release formulations to titrate dose. Total daily morphine dose may be administered in 2 divided doses daily (every 12 hours) or in 3 divided doses daily (every 8 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weight-directed dosing: 0.3 to 0.6 mg/kg/dose every 12 hours (Berde 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate dosing; fixed dosing (Berde 2002):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Patient weight 20 to &lt;35 kg: 10 to 15 mg every 8 to 12 hours; <b>Note:</b> 10 mg strength not available in US.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Patient weight 35 to &lt;50 kg: 15 to 30 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Patient weight &ge;50 kg: 30 to 45 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Discontinuation of extended release formulations:</i> In general, gradually titrate dose downward (eg, every 2 to 4 days). Do not discontinue abruptly.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from other oral morphine formulations to extended release formulations: </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Avinza: Adolescents &ge;18 years: Total daily morphine dose  administered once daily. The first dose of Avinza may be taken with the last dose of the immediate release morphine. Maximum daily dose: 1,600 mg/<b>day</b> due to fumaric acid content</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Kadian: Adolescents &ge;18 years: Total daily oral morphine dose may be either administered once daily or in 2 divided doses daily (every 12 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">MS Contin: Children and Adolescents: Total daily oral morphine dose may be administered either in 2 divided doses daily (every 12 hours) <b>or</b> in 3 divided doses (every 8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from parenteral morphine or other opioids to controlled/extended release formulations:</i> Substantial interpatient variability exists in relative potency. Therefore, it is safer to underestimate a patient's daily oral morphine requirement and provide breakthrough pain relief with immediate release morphine than to overestimate requirements. Consider the parenteral to oral morphine ratio or other oral or parenteral opioids to oral morphine conversions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion, SubQ continuous infusion: Children and Adolescents: 0.01 to 0.04 mg/kg/<b>hour</b> (10 to 40 <b>mcg</b>/kg/<b>hour</b>) (APA 2012; Friedrichsdorf 2007; Golianu 2000); opioid-tolerate patients may require higher doses; in a small study of terminal pediatric oncology patients (n=8; age range: 3 to 16 years), the median required dose was 0.04 to 0.07 mg/kg/<b>hour</b> (40 to 70 <b>mcg</b>/kg/<b>hour</b>); range: 0.025 to 2.6 mg/kg/<b>hour</b> (Miser 1980); another study evaluating subcutaneous continuous infusion in children with cancer (n=17; age range: 22 months to 22 years) had similar findings; median dose: 0.06 mg/kg/<b>hour</b> (60 <b>mcg</b>/kg/<b>hour</b>); range: 0.025 to 1.79 mg/kg/<b>hour</b> (Miser 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Conversion from intermittent IV morphine: Administer the patient's total daily IV morphine dose over 24 hours as a continuous infusion; titrate dose to appropriate effect</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sickle cell disease, acute crisis; opioid na&iuml;ve patients</b> (APS 1999; NHLBI 2014): <b>Note:</b> Individualize dose; titrate to effect; Infants &ge;6 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient weight &lt;50 kg: Initial: IV: 0.1 to 0.15 mg/kg every 2 to 4 hours; maximum dose: 7.5 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient weight &ge;50 kg: Initial: IV: 5 to 10 mg every 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tetralogy of fallot, hypercyanotic spell (infundibular spasm):</b> Infants and Children: Limited data available: IM, IV, SubQ: 0.1 mg/kg has been used to decrease ventilatory drive and systemic venous return (Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Palliative care, dyspnea management:</b> Limited data available: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inhalation (nebulization; preservative-free injection): Dose should be individualized and is dependent upon patient's previous or current systemic opioid exposure; doses not intended to provide analgesic activity; current systemic analgesia should be continued: Initial dose: Equivalent to patient's 4-hour systemic morphine requirement (eg, IV or oral dose); titrate to effect (Golianu 2000); every 4 to 6 hour administration has been suggested (Cohen 2002). In the only pediatric case report (end-stage CF, age: 10 years, weight: 20 kg), an initial dose of 2.5 mg was used and final dose was 10 mg every 4 to 6 hours (Cohen 2002); from experience in adult patients, an initial dose of 5 mg has been used and reported range 2.5 to 30 mg administered up to every 4 hours (Ferraresi 2005; Shirk 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Initial: 25% of 4-hour intermittent dose; titrate until patient is comfortable (Golianu 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 0.1 mg/kg/dose every 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute pain (moderate to severe):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Oral (immediate release formulations):</i> Opioid-naive: Initial: <b>Note:</b> Usual dosage range: 10 to 30 mg every 4 hours as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Solution: 10 to 20 mg every 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Tablet: 15 to 30 mg every 4 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>IM, SubQ:</i>  <b>Note:</b> Repeated SubQ administration causes local tissue irritation, pain, and induration. The use of IM injections is no longer recommended, especially for repeated administration due to painful administration, variable absorption, and lag time to peak effect; other routes are more reliable and less painful (American Pain Society 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: Opioid-naive: 5 to 10 mg every 4 hours as needed; usual dosage range: 5 to 15 mg every 4 hours as needed. Patients with prior opioid exposure may require higher initial doses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>IV:</i> Initial: Opioid-naive: 2.5 to 5 mg/dose every 3 to 4 hours as needed; patients with prior opioid exposure may require higher initial doses. <b>Note:</b> Administration of 2 to 3 mg every 5 minutes until pain relief or if associated sedation, oxygen saturation &lt;95%, or serious adverse event occurs may be appropriate in treating acute moderate to severe pain in settings such as the immediate postoperative period or the emergency department (Aubrun 2012; Lvovschi 2008); dose reduction in the immediate postoperative period (postanesthesia care unit) in the elderly is usually not necessary (Aubrun 2002). A maximum cumulative dose (eg, 10 mg) prompting reevaluation of continued morphine use and/or dose should be included as part of any medication order intended for short-term use (eg, PACU orders). Refer to institution-specific protocols as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuous IV infusion, SubQ continuous infusion:</i> Opioid tolerant: 0.8 to 10 mg/hour; may increase depending on pain relief/adverse effects; usual range up to 80 mg/hour. <b>Note:</b> May administer a loading dose (amount administered should depend on severity of pain) prior to initiating the infusion. A continuous (basal) infusion is not recommended in an opioid-naive patient (ISMP 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patient-controlled analgesia (PCA): </i> <b>Note:</b> In opioid-na&iuml;ve patients, consider lower end of dosing range:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Usual concentration: 1 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Demand dose: Usual initial: 1 mg; usual range: 0.5 to 2.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lockout interval: 5 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pain management:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Epidural:</i>  <b>Note: Use preservative-free formulation</b>; use lower doses and with extreme caution in debilitated patients. Vigilant monitoring is particularly important in these patients:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Single dose: <b>Lumbar region:</b> Astramorph/PF, Duramorph: 30 to 100 <b>mcg</b>/kg (optimal range: 2.5 to 3.75 mg; may depend upon patient comorbidities; Bujedo 2012; Sultan 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Continuous infusion (may be combined with bupivacaine): 0.2 to 0.4 mg/hour (Bujedo 2012). According to the manufacturer, Duramorph is not for use in continuous microinfusion devices.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Continuous microinfusion (Infumorph):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Opioid-naive: Initial: 3.5 to 7.5 mg over 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Opioid-tolerant: Initial: 4.5 to 10 mg over 24 hours, titrate to effect; usual maximum is ~30 mg per 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Intrathecal:</i>  <b>Note: Must use preservative-free formulation</b>; use extreme caution and in reduced dosage to debilitated patients. Intrathecal dose is usually <sup>1</sup>/<sub>10</sub> (one-tenth) that of epidural dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Opioid-naive: Single dose: <b>Lumbar region:</b> Astramorph/PF, Duramorph:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer's labeling: 0.2 to 1 mg may provide satisfactory pain relief for up to 24 hours. (Caution: This is only 0.4 to 2 mL of the 0.5 mg/mL potency or 0.2 to 1 mL of the 1 mg/mL potency.) Do not inject intrathecally more than 2 mL of the 0.5 mg/mL potency or 1 mL of the 1 mg/mL potency; repeat doses are not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate dosing: 0.1 to 0.3 mg (may provide adequate relief for up to 24 hours; APS 2008); repeat doses <b>not</b> recommended. If pain recurs within 24 hours of administration, use of an alternate route of administration is recommended. <b>Note:</b> Although product labeling recommends doses up to 1 mg, an analgesic ceiling exists with doses &gt;0.3 mg and the risk of respiratory depression is higher with doses &gt;0.3 mg (Rathmell 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous microinfusion (Infumorph): <b>Lumbar region:</b> After initial in-hospital evaluation of response to single-dose injections (Astramorph/PF, Duramorph) the initial dose of Infumorph is 0.2 to 1 mg over 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Opioid-tolerant: Continuous microinfusion (Infumorph): <b>Lumbar region:</b> Dosage range: 1 to 10 mg over 24 hours, titrate to effect; usual maximum: ~20 mg over 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> Limited experience with continuous intrathecal infusion of morphine has shown that the daily doses have to be increased over time. Employ doses &gt;20 mg/day with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Rectal:</i> 10 to 20 mg every 3 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic pain: Note:</b> Patients taking opioids chronically may become tolerant and require doses higher than the usual dosage range to maintain the desired effect. Tolerance can be managed by appropriate dose titration. There is no optimal or maximal dose for morphine in chronic pain. The appropriate dose is one that relieves pain throughout its dosing interval without causing unmanageable side effects. Consider total daily dose, potency, prior opioid use, degree of opioid experience and tolerance, conversion from previous opioid (including opioid formulation), patient's general condition, concurrent medications, and type and severity of pain during prescribing process.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (extended release formulations): A patient's morphine requirement should be established using immediate release formulations. Conversion to long-acting products may be considered when chronic, continuous treatment is required. Higher dosages should be reserved for use only in opioid-tolerant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Capsules, extended release (Avinza): </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Opioid-naive: Initial: 30 mg once daily; adjust in increments &le;30 mg daily every 4 days administered once daily (for best results, administer at same time each day)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Capsules, extended release (Kadian):</i> <b>Note:</b> Not intended for use as an initial opioid in the management of pain; use immediate release formulations before initiation. Total daily oral morphine dose may be either administered once daily or in 2 divided doses daily (every 12 hours). The first dose of Kadian may be taken with the last dose of the immediate release morphine.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Tablets, extended release (MS Contin):</i> Daily dose divided and administered every 8 or every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Discontinuation of extended release formulations:</i> In general, gradually titrate dose downward (eg, every 2 to 4 days). Do not  discontinue abruptly.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from other oral morphine formulations to extended release formulations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Avinza: Total daily morphine dose  administered once daily. The first dose of Avinza may be taken with the last dose of the immediate release morphine. Maximum: 1,600 mg/day due to fumaric acid content</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Kadian: Total daily oral morphine dose may be either administered once daily or in 2 divided doses daily (every 12 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">MS Contin: Total daily oral morphine dose may be administered either in 2 divided doses daily (every 12 hours) or in 3 divided doses (every 8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from parenteral morphine or other opioids to extended release formulations:</i> Substantial interpatient variability exists in relative potency. Therefore, it is safer to underestimate a patient's daily oral morphine requirement and provide breakthrough pain relief with immediate release morphine than to overestimate requirements. Consider the parenteral to oral morphine ratio or other oral or parenteral opioids to oral morphine conversions.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Parenteral to oral morphine ratio: Between 2 to 6 mg of oral morphine may be required for analgesia equivalent to 1 mg of parenteral morphine. An oral dose 3 times the daily parenteral dose may be sufficient in chronic pain settings.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Other parenteral or oral nonmorphine opioids to oral morphine: Specific recommendations are not available; refer to published relative potency data realizing that such ratios are only approximations. In general, it is safest to administer half of the estimated daily morphine requirement as the initial dose, and to manage inadequate analgesia by supplementation with immediate-release morphine.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from methadone to extended-release formulations:</i> Close monitoring is required when converting methadone to another opioid. Ratio between methadone and other opioid agonists varies widely according to previous dose exposure. Methadone has a long half-life and can accumulate in the plasma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b> According to the manufacturers' labeling, no specific dosage adjustments are provided (all formulations). In general, the manufacturers recommend starting cautiously with lower doses; titrating slowly while carefully monitoring for side effects. However, the choice of an alternate opioid may be prudent in patients with baseline renal impairment or rapidly changing renal function especially since other analgesics may be safer and reduced initial morphine dosing may result in suboptimal analgesia.  Although clearance of morphine is similar to patients with normal renal function, morphine glucuronide metabolites (M3G [inactive as an analgesic; may contribute to CNS stimulation] and M6G [active analgesic]) accumulate in renal impairment resulting in increased sensitivity; patients may experience severe and prolonged respiratory depression which may even be delayed (Lugo 2002; Niscola 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling. Pharmacokinetics are unchanged in mild liver disease; substantial extrahepatic metabolism may occur. In cirrhosis, increases in half-life and AUC suggest dosage adjustment required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776907\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AVINza: 30 mg [DSC] [contains fd&amp;c yellow #10 (quinoline yellow), fumaric acid]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AVINza: 45 mg [DSC] [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AVINza: 60 mg [DSC] [contains fumaric acid]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AVINza: 75 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AVINza: 90 mg [DSC] [contains fd&amp;c red #40, fumaric acid]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AVINza: 120 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fumaric acid]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 10 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 20 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 30 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 40 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 50 mg, 60 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 70 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 80 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 100 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 130 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 150 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 30 mg, 45 mg, 50 mg, 60 mg, 75 mg, 80 mg, 90 mg, 100 mg, 120 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Device, Intramuscular, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/0.7 mL (0.7 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (1 mL [DSC]); 8 mg/mL (1 mL [DSC]); 10 mg/mL (1 mL [DSC], 10 mL [DSC]); 15 mg/mL (1 mL [DSC], 20 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sulfate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Duramorph: 0.5 mg/mL (10 mL); 1 mg/mL (10 mL) [antioxidant free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infumorph 200: 200 mg/20 mL (10 mg/mL) (20 mL) [antioxidant free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infumorph 500: 500 mg/20 mL (25 mg/mL) (20 mL) [antioxidant free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg/mL (10 mL); 1 mg/mL (10 mL); 2 mg/mL (1 mL); 4 mg/mL (1 mL); 5 mg/mL (1 mL); 8 mg/mL (1 mL); 10 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (10 mL [DSC], 30 mL); 25 mg/mL (4 mL [DSC], 10 mL [DSC]); 50 mg/mL (20 mL, 50 mL); 1000 mg/100 mL (100 mL); 150 mg/150 mL in NaCl 0.9% (150 mL); 2,500 mg/250 mL in NaCl 0.9% (250 mL); 250 mg/250 mL in Dextrose 5% (250 mL); 250 mg/250 mL in NaCl 0.9% (250 mL); 250 mg/50 mL in NaCl 0.9% (50 mL); 50 mg/50 mL (50 mL); 500 mg/100 mL in NaCl 0.9% (100 mL); 500 mg/250 mL in NaCl 0.9% (250 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sulfate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (30 mL); 2 mg/mL (1 mL); 4 mg/mL (1 mL); 150 mg/30 mL (30 mL); 8 mg/mL (1 mL); 10 mg/mL (1 mL); 15 mg/mL (1 mL [DSC]); 25 mg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/5 mL (5 mL, 15 mL, 100 mL, 500 mL); 20 mg/5 mL (5 mL, 100 mL, 500 mL); 20 mg/mL (30 mL, 120 mL); 100 mg/5 mL (15 mL, 30 mL, 120 mL, 240 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg/mL (1 mL); 150 mg/30 mL in NaCl 0.9% (30 mL); 2 mg/2 mL in NaCl 0.9% (2 mL); 275 mg/55 mL in NaCl 0.9% (55 mL); 5 mg/5 mL in NaCl 0.9% (5 mL); 50 mg/25 mL in Dextrose 5% (25 mL); 50 mg/50 mL (50 mL); 60 mg/30 mL in NaCl 0.9% (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suppository, Rectal, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg (12 ea); 10 mg (12 ea); 20 mg (12 ea); 30 mg (12 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg, 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet ER 12 Hour Abuse-Deterrent, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MorphaBond ER: 15 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MorphaBond ER: 30 mg [contains fd&amp;c blue #2 (indigotine), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MorphaBond ER: 60 mg [contains fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MorphaBond ER: 100 mg [contains fd&amp;c blue #2 (indigotine), fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MS Contin: 15 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MS Contin: 30 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MS Contin: 60 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MS Contin: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MS Contin: 200 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg, 30 mg, 60 mg, 100 mg, 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release Abuse-Deterrent, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Arymo ER: 15 mg (100 ea); 30 mg (100 ea) [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Arymo ER: 60 mg (100 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776646\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776634\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9845085\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AVINza: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM311346.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WfLLbuiSptjHFvx0tBMz99w==&amp;TOPIC_ID=16024\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM311346.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Kadian:<a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020616s057lbl.pdf#page=33&amp;token=X+Qadbu+uicdz0daAyMxYka/8clP0SQ/uUAH41cn84OmPa25HU0uSHsazJdIaTVaQzkBJ02CFJuMOJlYxUMFFlbDJLj48S3WvBmaftwInJQ+QcjW8HWc3UsB3vCiJw13&amp;TOPIC_ID=16024\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020616s057lbl.pdf#page=33</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MorphaBond: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206544s002s005lbl.pdf#page=34&amp;token=UwXgf47ybr+yCVG1bBZq+T+JU9oPg80u4dp9/g/tQjDzqJF/a1pIeaKLThF5Ssf3TsPPeBuGbmZCRWvSKZGGIAmYQPZA9FsIDwtjwPg+gCDfYhfj004Y3VEl9jK3Uui3&amp;TOPIC_ID=16024\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206544s002s005lbl.pdf#page=34</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MS Contin: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM311374.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WBLbgrqQDKO3cCTU5ToIPnA==&amp;TOPIC_ID=16024\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM311374.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral solution: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201517s009lbl.pdf#page=26&amp;token=m+FA7jwtgxoYKyM9u9rVS45+tptraUDNDVYY+hrPoJDIdq172kCZOO5tNQEf18Mc0QMdmtKs/Xp3WtQKdpfEkcRv92TkLdrzdAVwsOCsMR+MmmFIfC9pwLaphEsWmE7U&amp;TOPIC_ID=16024\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201517s009lbl.pdf#page=26</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10512363\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer with food</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release: Oral solution: Available in multiple strengths, including a concentrated oral solution (20 mg/mL). Precautions should be taken to avoid confusion between the different concentrations; prescriptions should have the concentration specified as well as the dose clearly represented as milligram (mg) of morphine, not volume (mL). The enclosed calibrated oral syringe should always be used to administer the concentrated oral solution to ensure the dose is measured and administered accurately. The concentrated oral solution (20 mg/mL) should only be used in opioid-tolerant patients (adults taking &ge;60 mg/day of morphine or equivalent for &ge;1 week).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended/controlled  release products: Do not chew, crush, break, or dissolve extended and controlled release products; swallow whole. Avinza and Kadian capsules may be opened and contents sprinkled on a small amount of applesauce and eaten immediately without chewing; rinse mouth with water and swallow to ensure all beads have been ingested; do not chew, crush, or dissolve beads or pellets from capsule as it can result in a rapid release and absorption of a potentially fatal dose of morphine. Kadian capsules may be opened and contents sprinkled into ~10 mL of water, then flushed while swirling through a prewetted 16-French gastrostomy tube fitted with a funnel at the port end; flush with water to transfer all pellets and flush the tube; do not attempt to administer via NG tube. Do not administer Avinza with alcohol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: <b>Note:</b> Solutions for injection should be visually inspected for particulate matter and discoloration prior to administration. Do not use if contains a precipitate or is darker in color than pale yellow or discolored in any other way. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV push: Administer undiluted or diluted solution over 4 to 5 minutes (Gahart 2014); rapid IV administration may increase adverse effects </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intermittent IV infusion: Further dilute and administer over 15 to 30 minutes  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous IV infusion: Administer as a continuous infusion via an infusion pump.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epidural and intrathecal: <b>Use only preservative-free injections.</b> Adults: Infumorph was developed for use in continuous microinfusion devices only; it may require dilution before use, as determined by the individual patient's dosage requirements and the characteristics of the continuous microinfusion device; not recommended for single dose IV, IM, or SubQ administration; filter through &le;5 micron microfilter before injecting into microinfusion device. Astramorph/PF may be administered as a continuous infusion via the epidural route only. Duramorph is not for use in continuous microinfusion devices.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Inhalation: Limited data available; utilize preservative free parenteral morphine and further dilute prior to administration (Cohen 2002; Ferraresi 2005; Shirk 2006)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472939\" class=\"block uicn drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 0.1 mg/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472938\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 0.1 mg/mL, 0.5 mg/mL, <b>or</b> 1 mg/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776743\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not freeze. Store in carton until use. Protect from light. Degradation depends on pH and presence of oxygen; relatively stable in pH &le;4. Darkening of solutions indicate degradation. Do not heat-sterilize.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect capsules from light and moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suppositories: Store below 25&deg;C (77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10512350\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release formulations (oral solution and tablets): Management of moderate to severe acute and chronic pain (FDA approved in ages &ge;18 years and adults); has also been used for treatment of neonatal abstinence syndrome, iatrogenic opioid withdrawal, and palliative care management of dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Controlled and extended release products (eg, Avinza, Kadian, MS Contin): Management of moderate to severe <b>chronic</b> pain when continuous, around-the-clock opioid analgesia is required for an extended amount of time (FDA approved in ages &ge;18 years and adults); <b>Note:</b> Not intended for use as a PRN analgesic or for treatment of mild pain, acute pain, pain that is not expected to persist for an extended period of time, or for immediate postoperative pain (within 12-24 hours after surgery) unless the patient is already receiving chronic opioid therapy prior to surgery or if postoperative pain is expected to be moderate to severe and persist for an extended period of time</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intravenous: Management of severe acute pain; preanesthetic sedative [FDA approved in pediatric patients (age not specified) and adults]; has also been used for management of hypercyanotic spells associate with tetralogy of Fallot; and for palliative care management of dyspnea (including nebulization)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Epidural (at the lumbar level): Management of pain unresponsive to nonopioid analgesics (Astramorph/PF, Duramorph: FDA approved in adults); treatment of intractable chronic pain as an epidural infusion via microinfusion device (Infumorph: FDA approved in adults) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intrathecal (at lumbar level): Management of pain unresponsive to nonopioid analgesics (Astramorph/PF, Duramorph: FDA approved in adults); treatment of intractable chronic pain as a continuous infusion via microinfusion device (Infumorph: FDA approved in adults) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal: Suppositories: Management of severe acute and chronic pain (FDA approved in adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775520\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Morphine may be confused with HYDROmorphone, methadone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Morphine sulfate may be confused with magnesium sulfate</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Kadian may be confused with Kapidex [DSC]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">MS Contin may be confused with OxyCONTIN</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">MSO<sub>4</sub> and MS are error-prone abbreviations (mistaken as magnesium sulfate)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">AVINza may be confused with Evista, INVanz</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Roxanol may be confused with OxyFast, Roxicet, Roxicodone</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Use care when prescribing and/or administering morphine solutions. These products are available in different concentrations. Always prescribe dosage in mg; <b>not</b> by volume (mL).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Use caution when selecting a morphine formulation for use in neurologic infusion pumps (eg, Medtronic delivery systems). The product should be appropriately labeled as &ldquo;preservative-free&rdquo; and suitable for intraspinal use via continuous infusion. In addition, the product should be formulated in a pH range that is compatible with the device operation specifications.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776724\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrial fibrillation (oral), bradycardia (oral, rectal), chest pain (oral), circulatory depression (oral, IV), edema (oral, rectal), facial flushing (oral, rectal), flushing (oral), hypertension (oral), hypotension (oral), orthostatic hypotension (IM, IV), palpitations (oral, rectal), peripheral edema, peripheral vascular insufficiency (IV), phlebitis (IV), presyncope (oral, rectal), shock, syncope (oral, rectal), tachycardia (oral), vasodilatation (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal dreams (oral), abnormal gait (oral), abnormality in thinking (oral), agitation (oral, rectal), altered mental status (IV), amnesia (oral), anxiety, apathy (oral), ataxia (oral), chills (oral), coma (oral), confusion, decreased cough reflex, delirium (oral), depression (oral), disorientation (oral, rectal), disruption of body temperature regulation (IV, epidural, intrathecal), dizziness, drowsiness (oral), dysphoria, dyssynergia (oral), euphoria, fear (IV), feeling abnormal (oral), hallucination (oral), headache, hypoesthesia (oral), increased catecholamines (IV, epidural, intrathecal), increased intracranial pressure (oral), insomnia (oral, rectal), lack of concentration (oral), lethargy (oral), malaise (oral), mood changes (oral), myoclonus, nervousness (oral), pain (oral), paradoxical central nervous system stimulation (IV, epidural, intrathecal), paresthesia (oral), sedation (oral, rectal), seizure, slurred speech (oral), toxic psychosis (IM, IV, epidural, intrathecal), vertigo (oral), voice disorder (oral), withdrawal syndrome (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Decubitus ulcer (oral), diaphoresis (oral, rectal), hemorrhagic urticaria (IV, rectal), pallor (oral), pruritus, skin rash (oral, rectal), urticaria, xeroderma (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Amenorrhea (oral), antidiuretic effect (oral, rectal), decreased libido (oral, rectal), gynecomastia (oral), hyponatremia (oral), increased thirst (oral), SIADH (oral), weight loss (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (oral), anorexia (oral, rectal), biliary colic (oral), biliary tract spasm (rectal), constipation, decreased appetite (IV), delayed gastric emptying (oral), diarrhea, dysgeusia (oral), dyspepsia (oral), dysphagia (oral), gastric atony (oral), gastroenteritis (oral), gastroesophageal reflux disease (oral), gastrointestinal hypermotility (IV; in patients with chronic ulcerative colitis), hiccups (oral), nausea, rectal disease (oral), toxic megacolon (IV; patients with chronic ulcerative colitis), vomiting, xerostomia (oral, rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysuria (oral), ejaculatory disorder (oral), erectile dysfunction (IV), hypogonadism (oral), impotence (oral), oliguria, ureteral spasm (IV), urinary hesitancy (oral, rectal), urinary retention, urine abnormality (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (oral), granuloma (IV, epidural, intrathecal), leukopenia (oral), thrombocytopenia (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased liver enzymes (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction (IM)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Erythema at injection site (IV), induration at injection site (SC), local irritation (IV, epidural, intrathecal), local swelling (IV, intrathecal, epidural; genital swelling in males following infusion device implant surgery), pain at injection site (SC), residual mass at injection site (inflammatory; IV, epidural, intrathecal)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia (oral), back pain (oral), bone pain (oral), decreased bone mineral density (oral), foot-drop (oral), laryngospasm (oral), muscle rigidity (oral), muscle spasm (IV, epidural, intrathecal; myoclonic spasm of lower extremities), muscle twitching (oral), tremor (oral), vesicle sphincter spasm (IV), weakness (oral, rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Amblyopia (oral), blurred vision (oral), conjunctivitis (oral), diplopia (oral), eye pain (oral), miosis (oral, IV), nystagmus (oral), visual disturbance (oral, rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea (oral, IV), asthma (oral), atelectasis (oral), dyspnea, flu-like symptoms (oral), hypoventilation, hypoxia (oral), pulmonary edema (oral; includes noncardiogenic), respiratory depression (IV, epidural, intrathecal), respiratory insufficiency (oral), rhinitis (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Accidental injury (oral), fever (oral), impaired physical performance (IV), increased severity of condition (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, bronchospasm, dehydration, difficulty thinking, fatigue, hyperalgesia, hypersensitivity reaction, hypertonia, increased serum prolactin (Molitch 2008; Vuong 2010), intestinal obstruction, sepsis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776704\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis) to morphine or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days; GI obstruction, including paralytic ileus (known or suspected).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for opioids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Additional contraindications:</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Epidural/intrathecal: Infection at infusion site; concomitant anticoagulant therapy; uncontrolled bleeding diathesis; presence of any other concomitant therapy or medical condition that would render administration hazardous; upper airway obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal: Severe CNS depression; cardiac arrhythmias, heart failure due to chronic lung disease; increased intracranial or cerebrospinal pressure, head injuries, brain tumor; acute alcoholism, delirium tremens; seizure disorder; use after biliary tract surgery, suspected surgical abdomen, surgical anastomosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Contraindications may vary per product labeling; refer also to product labels: Suspected surgical abdomen (eg, acute appendicitis, pancreatitis); disease/condition that affects bowel transit (known or suspected); chronic obstructive airway; status asthmaticus; management of acute pain, including use in outpatient or day surgeries; mild, intermittent, or short-duration pain that can be managed with other pain medications; acute respiratory depression; hypercarbia; cor pulmonale; acute alcoholism; delirium tremens; convulsive disorders; severe CNS depression; increased cerebrospinal; intracranial pressure; brain tumor; head injury; cardiac arrhythmias; pregnancy; use during labor and delivery; breastfeeding; toxic psychosis and severe kyphoscoliosis (Kadian 2015); severe cirrhosis (M-Ediat 2017); hypotension, (M-Eslon 2014), emotional instability and/or suicidal ideation (Statex 2016); surgical anastomosis (morphine sultafe inj Sandoz 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776705\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Some dosage forms may be contraindicated in patients with severe CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Constipation: May cause constipation which may be problematic in patients with unstable  angina and patients post-myocardial infarction. Consider preventive measures (eg, stool softener, increased fiber) to reduce the potential for constipation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), circulatory shock, or drugs that may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Avoid use in patients with circulatory shock. Some dosage forms may be contraindicated in patients with cardiac arrhythmias or heart failure due to chronic lung disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: <b>[US Boxed Warning]: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely for respiratory depression, especially during initiation or dose escalation. Swallow morphine ER formulations whole (or may sprinkle the contents of the  capsule on applesauce and swallow without chewing); crushing, chewing, or dissolving the ER formulations can cause rapid release and absorption of a potentially fatal dose of morphine.</b> Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison disease. Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction, infertility, mood disorders, and osteoporosis (Brennan 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction  or acute pancreatitis; opioids may cause constriction of sphincter of Oddi.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression/coma: Avoid use in patients with impaired consciousness or coma, as these patients are susceptible to intracranial effects of CO<sub>2</sub> retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delirium tremens: Use with caution in patients with delirium tremens. Some dosage forms may be contraindicated in patients with delirium tremens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur. Some dosage forms may be contraindicated in patients with increased intracranial or cerebrospinal pressure, head injuries, or brain tumor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mental health conditions: Use opioids with caution for chronic pain in patients with mental health conditions (eg, depression, anxiety disorders, post-traumatic stress disorder) due to increased risk for opioid use disorder and overdose; more frequent monitoring is recommended (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Use with caution in patients who are morbidly obese.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Use with caution in patients with toxic psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale and patients having a substantially decreased respiratory reserve, hypoxia, hypercarbia, or preexisting respiratory depression, particularly when initiating therapy and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sleep-disordered breathing: Use opioids with caution for chronic pain and titrate dosage cautiously in patients with risk factors for sleep-disordered breathing, including HF and obesity. Avoid opioids in patients with moderate to severe sleep-disordered breathing (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with seizure disorders; may cause or exacerbate preexisting seizures. Some dosage forms may be contraindicated in patients with seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzodiazepines or other CNS depressants: [<b>US Boxed Warning]: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of morphine and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosage and durations to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation.</b> Some dosage forms may be contraindicated in patients with acute alcoholism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Extended-release capsules:<b> [US Boxed Warning]: Patients should not consume alcoholic beverages or medication containing ethanol while taking ER capsules; ethanol may increase morphine plasma levels, resulting in a potentially fatal overdose.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; may be more sensitive to adverse effects, including life-threatening respiratory depression. Decrease initial dose. In the setting of chronic pain, monitor closely due to an increased potential for risks, including certain risks such as falls/fracture, cognitive impairment, and constipation. Clearance may also be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increasing the risk for respiratory depression or overdose (Dowell [CDC 2016]). Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Neonatal withdrawal syndrome: <b>[US Boxed Warning]: Prolonged maternal use of opioids during pregnancy can cause neonatal withdrawal syndrome in the newborn, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If prolonged opioid therapy is required in a pregnant woman, ensure treatment is available and warn patient of risk to the neonate.</b> Signs and symptoms include irritability, hyperactivity, abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, and failure to gain weight. Onset, duration, and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Infants &lt;3 months  of age, especially if premature, are more susceptible to respiratory depression and/or apnea; use with caution and generally in reduced doses in this age group (APS 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infumorph, Duramorph: Neuroaxial administration: <b>[US Boxed Warning]: </b><b>Because of the risk of severe adverse effects when the epidural or intrathecal route of administration is employed, patients must be observed in a fully equipped and staffed environment for at least 24 hours after the initial dose. Single-dose Duramorph neuraxial administration may result in acute or delayed respiratory depression for up to 24 hours. Monitor patients receiving Infumorph for the first several days after catheter implantation. </b>Naloxone injection should be immediately available. Thoracic epidural administration has been shown to dramatically increase the risk of early and late respiratory depression. High doses (&gt; 20 mg/day) of neuraxial morphine may produce myoclonic events.  Patients with reduced circulating blood volume or impaired myocardial function, or on concomitant sympatholytic drugs should be monitored for orthostatic hypotension, a frequent complication in single-dose neuraxial morphine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended-release formulations: Therapy should only be prescribed by health care professionals familiar with the use of potent opioids for chronic pain. Extended-release products are not interchangeable. When determining a generic equivalent or switching from one extended-release product to another, a thorough understanding of the pharmacokinetic properties is important in determining the proper generic equivalent or proper dose of the other extended-release product (review of the manufacturer's label may be necessary).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">-<i> Arymo ER: </i>Moistened tablets may become sticky, leading to difficulty in swallowing the tablets; choking, gagging, regurgitation, and tablets getting stuck in the throat may occur. Tablet stickiness and swelling may also predispose patients to intestinal obstruction and exacerbation of diverticulitis. Do not to pre-soak, lick, or otherwise wet tablets prior to placing in the mouth; take one tablet at a time with enough water to ensure complete swallowing. Consider use of an alternative analgesic in patients who have difficulty swallowing and patients at risk for underlying GI disorders resulting in a small GI lumen (eg, esophageal cancer, colon cancer).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <i>Avinza capsules:</i> Dosage form contains fumaric acid; dangerous quantities of fumaric acid may be ingested when &gt;1,600 mg/day is used. Serious renal toxicity may occur above the maximum dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral solution: Risk of medication errors: <b>[US Boxed Warning]: </b><b>Ensure accuracy when prescribing, dispensing, and administering morphine oral solution. Dosing errors due to confusion between mg and mL, and other morphine solutions of different concentrations, can result in accidental overdose and death.</b> The 100 mg per 5 mL (20 mg/mL) is for use in opioid-tolerant patients only.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injections: <b>[US Boxed Warning]: </b><b>Because of delay in maximum CNS effect with IV administration (30 minutes), rapid IV administration may result in overdosing. Observe patients in a fully equipped and staffed environment for at least 24 hours after each test dose of Infumorph and, as indicated, for the first several days after surgery. </b> Products are designed for administration by specific routes (ie, IV, intrathecal, epidural). Use caution when prescribing, dispensing, or administering to use formulations only by intended route(s). Rapid IV administration may result in chest wall rigidity. Use with caution when injecting IM into chilled areas or in patients with hypotension or shock (impaired perfusion may prevent complete absorption); if repeated injections are administered, an excessive amount may be suddenly absorbed if normal circulation is re-established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infumorph: Should only be used in microinfusion devices; not for IV, IM, or SubQ administration or for single-dose administration. Administer intrathecal doses of 10 and 25 mg/mL to the lumbar area. Monitor closely, especially in the first 24 hours. Inflammatory masses (eg, granulomas), some resulting in severe neurologic impairment, have occurred when receiving Infumorph via indwelling intrathecal catheter; monitor carefully for new neurologic signs/symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchange: Improper or erroneous substitution of Infumorph for regular Duramorph is likely to result in serious overdosage, leading to seizures, respiratory depression, and possibly a fatal outcome.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfites: Some dosage forms may contain sulfites that may cause allergic reactions in sulfite sensitive patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse/diversion: <b>[US Boxed Warning]: Morphine exposes patients and other users to the risks of addiction, abuse, and misuse, potentially leading to overdose and death. Assess each patient&rsquo;s risk prior to prescribing; monitor all patients regularly for development of these behaviors or conditions.</b> Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Other factors associated with increased risk include younger age, concomitant depression (major), and psychotropic medication use. Consider offering naloxone prescriptions in patients with factors associated with an increased risk for overdose, such as history of overdose or substance use disorder, higher opioid dosages (&ge;50 morphine milligram equivalents/day orally), and concomitant benzodiazepine use (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Accidental exposure: Oral: formulations: <b>[US Boxed Warning]: Accidental ingestion of even one dose, especially in children, can result in a fatal overdose of morphine.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Chronic pain (outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder) in outpatient setting in adults: Opioids should <b>not</b> be used as first-line therapy for chronic pain management (pain &gt;3-month duration or beyond time of normal tissue healing) due to limited short-term benefits, undetermined long-term benefits, and association with serious risks (eg, overdose, MI, auto accidents, risk of developing opioid use disorder).  Preferred management includes nonpharmacologic therapy and nonopioid therapy (eg, NSAIDS, acetaminophen, certain anticonvulsants and antidepressants). If opioid therapy is initiated, it should be combined with nonpharmacologic and nonopioid therapy, as appropriate. Prior to initiation, known risks of opioid therapy should be discussed and realistic treatment goals for pain/function should be established, including consideration for discontinuation if benefits do not outweigh risks. Therapy should be continued only if clinically meaningful improvement in pain/function outweighs risks.  Therapy should be initiated at the lowest effective dosage using immediate-release opioids (instead of extended-release/long-acting opioids). Risk associated with use increases with higher opioid dosages.  Risks and benefits should be re-evaluated when increasing dosage to &ge;50 morphine milligram equivalents (MME)/day orally; dosages &ge;90 MME/day orally should be avoided unless carefully justified (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: Opioids decrease bowel motility; monitor for decreased bowel motility in postop patients receiving opioids. Use with caution in the perioperative setting; individualize treatment when transitioning from parenteral to oral analgesics. Some dosage forms may be contraindicated after biliary tract surgery, suspected surgical abdomen, or surgical anastomosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Concurrent use of mixed agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol) or partial agonist (eg, buprenorphine) analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Taper dose gradually when discontinuing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26535459\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Prolonged use of any morphine product during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For postoperative tonsillectomy (with/without adenoidectomy) pain management in pediatric patients, morphine has been shown to have a higher risk of adverse effects compared to other analgesics without additional analgesic benefit; patient-specific risk factors for these adverse events are not fully defined (Biesiade 2014; Jimenez 2012; Kelly 2015; Ragjavendran 2010; Sadhasivam 2012). Data is preliminary and large-scale population-based generalizations and recommendations for practice have not been made. However, racial differences in adverse effects have been observed. A statistically significant higher incidence of adverse effects (pruritus, emesis) was reported in Latino children and adolescents following perioperative morphine administration than the comparative non-Latino Caucasian cohort (Jimenez 2012). In another trial, Caucasian children and adolescents receiving peri/postoperative morphine showed a higher incidence of postoperative pruritis and emesis than African-American patients (Sadhasivam 2012). The observed risk for respiratory depression between racial groups has been variable, with some data showing no racial difference in risk between Latino and non-Latino Caucasians or between Caucasians and African-American patients, while other data shows a higher risk in African-American pediatric patients compared to Caucasians (Biesiada 2014; Jimenez 2012, Sadhasivam 2012). Regardless of race, an overall higher and clinically significant incidence of respiratory depression has been observed in patients with sleep disturbances requiring tonsillectomy procedure (eg, obstructive sleep apnea); a lower initial dose has been suggested in these patients (Ragjavendran 2010). Current guidelines recommend that children and adolescents receive intravenous dexamethasone intraoperatively and effective therapy for postoperative tonsillectomy pain; NSAIDs (except ketorolac) can be used safely (AAO-HNS [Baugh 2011]). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776734\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor), P-glycoprotein/ABCB1, UGT1A1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776735\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16024&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alvimopan: Opioid Analgesics may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May enhance the analgesic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiplatelet Agents (P2Y12 Inhibitors): Morphine (Systemic) may diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Morphine (Systemic) may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors).  Management: Consider alternative anti-ischemic/analgesic therapies (eg, beta-blockers, nitroglycerin) in patients with acute coronary syndromes treated with a P2Y12 inhibitor when possible. The risks associated with other opioids are unknown.<b> Exceptions: </b>Cangrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the CNS depressant effect of Opioid Analgesics. Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Opioid Analgesics may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diuretics: Opioid Analgesics may enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Opioid Analgesics may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Esmolol: Morphine (Systemic) may increase the serum concentration of Esmolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gabapentin: May enhance the CNS depressant effect of Morphine (Systemic). Morphine (Systemic) may increase the serum concentration of Gabapentin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Opioid Analgesics may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Morphine (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: May diminish the therapeutic effect of Opioid Analgesics. Management: Avoid the concomitant use of nalmefene and opioid analgesics. Discontinue nalmefene 1 week prior to any anticipated use of opioid analgesics. If combined, larger doses of opioid analgesics will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naltrexone: May diminish the therapeutic effect of Opioid Analgesics. Management: Seek therapeutic alternatives to opioids.  See full drug interaction monograph for detailed recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Analgesics. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: Opioid Analgesics may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Opioid Analgesics may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Morphine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Opioid Analgesics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: May enhance the bradycardic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776739\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ethanol: Alcoholic beverages or ethanol-containing products may disrupt extended release formulation resulting in rapid release of entire morphine dose. Management: Avoid alcohol. <b>Do not administer Avinza or Kadian with alcoholic beverages or ethanol-containing prescription or nonprescription products.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Food: Administration of oral morphine solution with food may increase bioavailability (ie, a report of 34% increase in morphine AUC when morphine oral solution followed a high-fat meal). The bioavailability of Avinza, MorphaBond, MS Contin, or Kadian does not appear to be affected by food. Management: Take consistently with or without meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776700\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Prolonged maternal use of opioids during pregnancy can cause neonatal withdrawal syndrome in the newborn, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If prolonged opioid therapy is required in a pregnant woman, ensure treatment is available and warn patient of risk to the neonate.</b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Morphine crosses the placenta. Maternal use of opioids may be associated with birth defects, poor fetal growth, stillbirth, and preterm delivery (CDC [Dowell 2016]). If chronic opioid exposure occurs in pregnancy, adverse events in the newborn (including withdrawal) may occur (Chou 2009). Symptoms of neonatal abstinence syndrome (NAS) following opioid exposure may be autonomic (eg, fever, temperature instability), gastrointestinal (eg, diarrhea, vomiting, poor feeding/weight gain), or neurologic (eg, high-pitched crying, hyperactivity, increased muscle tone, increased wakefulness/abnormal sleep pattern, irritability, sneezing, seizure, tremor, yawning) (Dow 2012; Hudak 2012). Mothers who are physically dependent on opioids may give birth to Infants who are also physically dependent. Opioids may cause respiratory depression and psycho-physiologic effects in the neonate; newborns of mothers receiving opioids during labor should be monitored.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Morphine is commonly used for the treatment of pain during labor and immediately postpartum (ACOG 177 2017). Not all preparations are recommended for use and morphine should not be used when other analgesic techniques are more appropriate. Agents other than morphine are used to treat chronic non-cancer pain in pregnant women or those who may become pregnant (CDC [Dowell 2016]; Chou 2009; Kahan 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10512364\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Respiratory rate; oxygen saturation; mental status; blood pressure; heart rate; pain relief; signs of misuse, abuse, and addiction; level of sedation; signs or symptoms of hypogonadism or hypoadrenalism with long term use (Brennan 2013)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Chronic pain (long-term therapy outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder): Evaluate benefits/risks of opioid therapy within 1 to 4 weeks of treatment initiation and with dose increases. Re-evaluate benefits/risks every 3 months during therapy or more frequently in patients at increased risk of overdose or opioid use disorder. Urine drug testing is recommended prior to initiation and with consideration for re-checking at least yearly (includes controlled prescription medications and illicit drugs of abuse). State prescription drug monitoring program (PDMP) data should be reviewed by clinicians prior to initiation and periodically during therapy (frequency ranging from every prescription to every 3 months) (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Astramorph/PF, Duramorph, Infumorph: Patients should be observed in a fully equipped and staffed environment for at least 24 hours following initiation, and as appropriate for the first several days after catheter implantation. Naloxone injection should be immediately available. Patient should remain in this environment for at least 24 hours following the initial dose. For patients receiving Infumorph via microinfusion device, patient may be observed, as appropriate, for the first several days after catheter implantation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Alternative monitoring recommendations</i></b> (Bujedo 2012): Epidural: <b>Note:</b> All patients receiving neuraxial opioids should be monitored for adequate ventilation (eg, respiratory rate, depth of respiration [without disturbing patient]), oxygenation (eg, pulse oximetry when appropriate), and level of consciousness.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Single dose:</i> Monitor patient for a minimum of 24 hours after administration with a frequency of at least once per hour for the first 12 hours after administration, followed by at least once every 2 hours for the next 12 hours (ie, from 12 to 24 hours after administration). After 24 hours, frequency dictated by overall clinical condition and concurrent medications.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuous infusion or patient controlled epidural analgesia (PCEA):</i> Monitor patient during the entire duration of the infusion with a frequency of at least once per hour for the first 12 hours, followed by at least once every 2 hours for the next 12 hours (ie, from 12 to 24 hours after administration). After 24 hours, monitor at least once every 4 hours. After discontinuation of infusion or PCEA, frequency dictated by overall clinical condition and concurrent medications.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Also refer to institution specific protocols as appropriate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776768\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to opioid receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776772\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action (patient dependent; dosing must be individualized): Oral (immediate release): ~30 minutes; IV: 5 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration (patient dependent; dosing must be individualized): Pain relief:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate-release formulations (tablet, oral solution, injection): 3 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended-release capsule and tablet: 8 to 24 hours (formulation dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epidural or intrathecal: Single dose: Up to 24 hours (Bujedo 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suppository: 3 to 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Variable</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributes to skeletal muscle, liver, kidneys, lungs, intestinal tract, spleen and brain; V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cancer patients (children age: 1.7 to 18.7 years): Median: 5.2 L/kg; a significantly higher V<sub>d</sub> was observed in children &lt;11 years (median: 7.1 L/kg) versus &gt;11 years (median: 4.7 L/kg) (Hunt 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 1 to 6 L/kg; binds to opioid receptors in the CNS and periphery (eg, GI tract)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Premature Infants: &lt;20%; Adults: 20% to 35%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via conjugation with glucuronic acid primarily to morphine-6-glucuronide (M6G) (active analgesic) morphine-3-glucuronide (M3G) (inactive as analgesic; may contribute to CNS stimulation [Lugo 2002]); minor metabolites include morphine-3-6-diglucuronide; other minor metabolites include normorphine (active) and morphine 3-ethereal sulfate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 17% to 33% (first-pass effect limits oral bioavailability; oral:parenteral effectiveness reportedly varies from 1:6 in opioid-naive patients to 1:3 with chronic use); Nebulization: 5.5 &plusmn; 3.2% (Masood 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preterm: 10 to 20 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: 7.6 hours (range: 4.5 to 13.3 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 1 to 3 months: Median: 6.2 hours (range: 5 to 10 hours) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 3 to 6 months: Median: 4.5 hours (range: 3.8 to 7.3 hours) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 6 months to Children 2.5 years: Median: 2.9 hours (range: 1.4 to 7.8 hours) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preschool Children: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children with sickle cell disease (age: 6 to 19 years): ~1.3 hours (Dampier 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Immediate-release forms: 2 to 4 hours; Avinza: ~24 hours;  Kadian: 11 to 13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Tablets, oral solution, epidural: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Extended release tablets: 3 to 4 hours; Avinza: 30 minutes (maintained for 24 hours); Kadian: ~10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Suppository: 20 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">SubQ: 50 to 90 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM: 30 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: 20 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cerebrospinal fluid: After an oral dose of controlled release morphine concentrations peak at 8 hours for both normal and reduced renal function; morphine-6-glucuronide (active analgesic) and morphine-3-glucuronide distribution into the CNS may be delayed peaking at 12 hours in patients with normal renal function or up to 24 hours in patients with ESRD (peak level of morphine-6-glucuronide is ~15 times higher than patients with normal renal function) (D'Honneur 1994).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (primarily as morphine-3-glucuronide, neonates: 3% to 15%; adults: ~2% to 12% excreted unchanged); feces (~7% to 10%). It has been suggested that accumulation of morphine-6-glucuronide might cause toxicity with renal insufficiency. All of the metabolites (ie, morphine-3-glucuronide, morphine-6-glucuronide, and normorphine) have been suggested as possible causes of neurotoxicity (eg, myoclonus).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance: <b>Note:</b> In pediatric patients, adult values are reached by 6 months to 2.5 years of age (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preterm: 0.5 to 3 mL/minute/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates 1 to 7 days: Median: 5.5 mL/minute/kg (range: 3.2 to 8.4 mL/minute/kg) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates 8 to 30 days: Median: 7.4 mL/minute/kg (range: 3.4 to 13.8 mL/minute/kg) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 1 to 3 months: Median: 10.5 mL/minute/kg (range: 9.8 to 20.1 mL/minute/kg) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 3 to 6 months: Median: 13.9 mL/minute/kg (range: 8.3 to 24.1 mL/minute/kg) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 6 months to Children 2.5 years: Median: 21.7 mL/minute/kg (range: 5.8 to 28.6 mL/minute/kg) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preschool Children: 20 to 40 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cancer patients (Children age 1.7 to 18.7 years): Median: 23.1 mL/minute/kg; a significantly higher clearance was observed in children &lt;11 years (median: 37.4 mL/minute/kg) versus &gt;11 years (median: 21.9 mL/minute/kg) (Hunt 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children with sickle cell disease (age: 6 to 19 years): ~36 mL/minute/kg (range: 6 to 59 mL/minute/kg) (Dampier 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 20 to 30 mL/minute/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10512367\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Equianalgesic doses: Codeine: 120 mg IM = morphine 10 mg IM = single dose oral morphine 60 mg or chronic dosing oral morphine 15 to 25 mg</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Avinza capsules contain both immediate release and extended release beads; also contains fumaric acid (as an osmotic agent and local pH modifier); this product is intended for once daily oral administration only; not for PRN or postoperative use. Kadian capsules contain extended release pellets that are polymer-coated; this product is intended for every 12- or 24-hour dosing. Kadian capsules also contain talc; parenteral abuse may result in local tissue necrosis, infection, pulmonary granulomas, endocarditis, and valvular heart injury.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45042893\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>0.4 mg/mL (400 mcg/mL) Oral Solution (ASHP 2017)</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 0.4 mg/mL oral solution may be made using the <b>2 mg/mL</b> oral morphine solution. Measure 10 mL (20 mg) of the 2 mg/mL oral morphine solution and transfer to a plastic amber bottle. Measure 40 mL of sterile water for irrigation and add to bottle containing the morphine. Shake to mix. Store at room temperature. Stable for 60 days.</p>\n    <div class=\"reference\">Sauberan J, Rossi S, Kim JH. Stability of dilute oral morphine solution for neonatal abstinence syndrome. <i>J Addict Med</i>. 2013;7(2):113-115.<span class=\"pubmed-id\">23370932</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776910\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Kadian Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (60): $697.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (60): $769.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (60): $837.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (60): $1,117.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $1,400.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (60): $1,675.85</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (60): $2,232.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $2,753.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $5,657.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Morphine Sulfate ER Beads Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $572.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (100): $849.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $1,112.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $1,415.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (100): $1,672.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (100): $1,973.87</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Morphine Sulfate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (60): $283.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $522.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $568.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $950.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $1,137.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (100): $1,515.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $1,900.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Device</b> (Morphine Sulfate Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/0.7 mL (0.7 mL): $31.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Infumorph 200 Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 MG/20ML (10 mg/mL) (20 mL): $237.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Infumorph 500 Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 MG/20ML (25 mg/mL) (20 mL): $404.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate (Concentrate) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (30 mL): $25.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/mL (10 mL): $7.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (10 mL): $8.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (1 mL): $2.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/mL (1 mL): $2.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg/mL (1 mL): $2.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (1 mL): $2.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 5% (100 mL): $16.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250MG/250ML 5% (250 mL): $19.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (1 mL): $3.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/mL (1 mL): $3.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (1 mL): $3.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg/mL (1 mL): $3.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (1 mL): $3.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (30 mL): $9.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (10 mL): $8.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (20 mL): $13.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/5 mL (100 mL): $12.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/5 mL (100 mL): $17.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate-NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/50 mL 0.9% (50 mL): $22.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/100 mL 0.9% (100 mL): $30.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/50 mL 0.9% (50 mL): $15.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 0.9% (100 mL): $12.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150MG/150ML 0.9% (150 mL): $17.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250MG/250ML 0.9% (250 mL): $18.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg/100 mL 0.9% (100 mL): $24.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2500MG/250ML 0.9% (250 mL): $71.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Morphine Sulfate in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MG/25ML 5% (25 mL): $9.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Morphine Sulfate-NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/mL 0.9% (1 mL): $8.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2MG/2ML 0.9% (2 mL): $5.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Morphine Sulfate-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2MG/2ML 0.9% (2 mL): $4.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5MG/5ML 0.9% (5 mL): $5.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/50 mL 0.9% (50 mL): $11.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60MG/30ML 0.9% (30 mL): $11.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150MG/30ML 0.9% (30 mL): $11.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">275MG/55ML 0.9% (55 mL): $12.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suppository</b> (Morphine Sulfate Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (12): $60.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (12): $75.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (12): $90.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (12): $112.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet ER 12 Hour Abuse-Deterrent</b> (MorphaBond ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $648.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $1,296.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $2,037.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $3,396.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Extended Release Abuse-Deterrent</b> (Arymo ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $569.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $1,140.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $2,281.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Morphine Sulfate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $167.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $317.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $621.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $919.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $1,838.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (MS Contin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $433.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $823.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $1,606.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $2,378.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $4,355.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Morphine Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $43.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $74.71</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961991\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anamorph (AU);</li>\n      <li>Contalgin (DK, IS);</li>\n      <li>Depolan (FI);</li>\n      <li>Dimorf (BR);</li>\n      <li>Dimorf SP (PY);</li>\n      <li>Dolcontin (FI, SE);</li>\n      <li>Dolcontin Depottab (NO);</li>\n      <li>Doltard (DK, EE, LV);</li>\n      <li>Graten (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Kadian (BM);</li>\n      <li>Kapanol (AU);</li>\n      <li>La Morph (NZ);</li>\n      <li>M-Eslon (CL, CO, EC, PE);</li>\n      <li>M.I.R. (IL);</li>\n      <li>MCR (IL);</li>\n      <li>Morfex (BD);</li>\n      <li>Morficontin (GR);</li>\n      <li>Morgesic XR (BD);</li>\n      <li>Morphanton (DE);</li>\n      <li>Morphgesic (TR);</li>\n      <li>Morphgesic SR (GB, MT);</li>\n      <li>Moscontin (FR);</li>\n      <li>MS Contin (AU, BE, CN, IT, LU, NL, VE);</li>\n      <li>MS Contin CR (KR);</li>\n      <li>MS Mono (AU);</li>\n      <li>MSP (IL);</li>\n      <li>MST (PT);</li>\n      <li>MST Continus (AE, AR, BF, BG, BH, BJ, CI, CY, CZ, EE, EG, ES, ET, GB, GH, GM, GN, HK, HR, ID, IE, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, OM, PH, PK, PL, QA, RO, SA, SC, SD, SG, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>MST Continus Retard (CH);</li>\n      <li>Mundidol Retard (AT);</li>\n      <li>MXL (TW);</li>\n      <li>Oramorph (BE, ES, FR, GB, IE, LU, PT, SE);</li>\n      <li>P Guard (JP);</li>\n      <li>Pacif (JP);</li>\n      <li>RA-Morph (NZ);</li>\n      <li>Rumorf (IN);</li>\n      <li>S-Morphine (KR);</li>\n      <li>Sevredol (AU, CH, CZ, HR, IE, NZ, RO, SI, SK, TR);</li>\n      <li>Statex (SG);</li>\n      <li>Vendal (AT, UY);</li>\n      <li>Vendal Retard (LV);</li>\n      <li>Vermor (LK);</li>\n      <li>Zomorph (ES)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists Number 36, July 2002. Obstetric Analgesia and Anesthesia,&quot; <i>Obstet Gynecol</i>, 2002, 100(1):177-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/12100826/pubmed\" target=\"_blank\" id=\"12100826\">12100826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins&mdash;Obstetrics. Practice bulletin no. 177: obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2017;129(4):e73-e89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/28333819/pubmed\" target=\"_blank\" id=\"28333819\">28333819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anand KJ and International Evidence-Based Group for Neonatal Pain, &ldquo;Consensus Statement for the Prevention and Management of Pain in the Newborn,&rdquo; <i>Arch Pediatr Adolesc Med</i>, 2001, 155(2):173-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/11177093/pubmed\" target=\"_blank\" id=\"11177093\">11177093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Association of Paediatric Anaesthetists of Great Britain and Ireland (APA), &quot;Good Practice in Postoperative and Procedural Pain Management, 2nd edition,&quot; <i>Paediatr Anaesth</i>, 2012, 22(Suppl 1):1-79.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Astramorph/PF (morphine sulfate) [prescribing information]. Schaumburg, IL: APP Pharmaceuticals; June 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avinza (morphine sulfate) [prescribing information]. Gainesville, GA: Alkermes Gainesville; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aubrun F, Mazoit JX, Riou B. Postoperative intravenous morphine titration. <i>Br J Anaesth</i>. 2012;108(2):193-201.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/22250276/pubmed\" target=\"_blank\" id=\"22250276\">22250276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aubrun F, Monsel S, Langeron O, Coriat P, Riou B. Postoperative titration of intravenous morphine in the elderly patient. <i>Anesthesiology</i>. 2002;96(1):17-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/11752996 /pubmed\" target=\"_blank\" id=\"11752996 \">11752996 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baka NE, Bayoumeu F, Boutroy MJ, Laxenaire MC. Colostrum morphine concentrations during postcesarean intravenous patient-controlled analgesia. <i>Anesth Analg</i>. 2002;94(1):184-187.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/11772825/pubmed\" target=\"_blank\" id=\"11772825\">11772825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baugh RF, Archer SM, Mitchell RB, et al. American Academy of Otolaryngology-Head and Neck Surgery Foundation. Clinical practice guideline: tonsillectomy in children. <i>Otolaryngol Head Neck Surg</i>. 2011;144(1 Suppl):S1-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/21493257 /pubmed\" target=\"_blank\" id=\"21493257 \">21493257 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berde C, Ablin A, Glazer J, et al, &ldquo;American Academy of Pediatrics Report of the Subcommittee on Disease-Related Pain in Childhood Cancer,&rdquo; <i>Pediatrics</i>, 1990, 86(5 Pt 2):818-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/2216644/pubmed\" target=\"_blank\" id=\"2216644\">2216644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berde CB and Sethna NF, &quot;Analgesics for the Treatment of Pain in Children,&quot; <i>N Engl J Med</i>, 2002, 347(14):1094-103.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/12362012/pubmed\" target=\"_blank\" id=\"12362012\">12362012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biesiada J, Chidambaran V, Wagner M, et al. Genetic risk signatures of opioid-induced respiratory depression following pediatric tonsillectomy. <i>Pharmacogenomics</i>. 2014;15(14):1749-1762.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/25493568 /pubmed\" target=\"_blank\" id=\"25493568 \">25493568 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3) (Suppl 1):S12-S18. doi: 10.1016/j.amjmed.2012.12.001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/23414717/pubmed\" target=\"_blank\" id=\"23414717\">23414717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bujedo BM, &quot;A Clinical Approach to Neuroaxial Morphine for the Treatment of Postoperative Pain,&quot; <i>Pain Res Treat</i>, 2012, 8(3):177-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/23002426/pubmed\" target=\"_blank\" id=\"23002426\">23002426</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burgos AE and Burke, Jr BL , &quot;Neonatal Abstinence Syndrome,&quot; <i>Neoreviews</i>, 2009, 10(5):e222-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chou R, Fanciullo GJ, Fine PG, et al, &ldquo;Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain,&rdquo; <i>J Pain</i>, 2009, 10(2):113-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/19187889/pubmed\" target=\"_blank\" id=\"19187889\">19187889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen SP and Dawson TC, &quot;Nebulized Morphine as a Treatment for Dyspnea in a Child With Cystic Fibrosis,&quot; <i>Pediatrics</i>, 2002, 110(3):e38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/12205288/pubmed\" target=\"_blank\" id=\"12205288\">12205288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cramton RE and Gruchala NE, &quot;Managing Procedural Pain in Pediatric Patients,&quot; <i>Curr Opin Pediatr</i>, 2012, 24(4):530-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/22732639/pubmed\" target=\"_blank\" id=\"22732639\">22732639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dampier CD, Setty BN, Logan J, et al, &ldquo;Intravenous Morphine Pharmacokinetics in Pediatric Patients With Sickle Cell Disease,&rdquo; <i>J Pediatr</i>, 1995, 126(3):461-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/7869211 /pubmed\" target=\"_blank\" id=\"7869211 \">7869211 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    D'Honneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. <i>Anesthesiology</i>. 1994;81(1):87-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/8042814 /pubmed\" target=\"_blank\" id=\"8042814 \">8042814 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. <i>MMWR Recomm Rep</i>. 2016;65(1):1-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/26987082/pubmed\" target=\"_blank\" id=\"26987082\">26987082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dow K, Ordean A, Murphy-Oikonen J, et al, &quot;Neonatal Abstinence Syndrome Clinical Practice Guidelines For Ontario,&quot; <i>J Popul Ther Clin Pharmacol</i>, 2012, 19(3):e488-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/23241498/pubmed\" target=\"_blank\" id=\"23241498\">23241498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duramorph Preservative free (morphine sulfate injection) [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; August 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferraresi V, &quot;Inhaled Opioids for the Treatment of Dyspnea,&quot; <i>Am J Health Syst Pharm</i>, 2005, 62(3):319-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/15719593/pubmed\" target=\"_blank\" id=\"15719593\">15719593</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedrichsdorf SJ, Kang TI. The management of pain in children with life-limiting illnesses. <i>Pediatr Clin North Am</i>. 2007;54(5):645-672.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/17933616 /pubmed\" target=\"_blank\" id=\"17933616 \">17933616 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glare PA, Walsh TD. Clinical pharmacokinetics of morphine. <i>Ther Drug Monit</i>. 1991;13(1):1-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/2057987 /pubmed\" target=\"_blank\" id=\"2057987 \">2057987 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golianu B, Krane EJ, Galloway KS, Yaster M. Pediatric acute pain management. <i>Pediatr Clin North Am</i>. 2000;47(3):559-587.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/10835991 /pubmed\" target=\"_blank\" id=\"10835991 \">10835991 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Guidelines for the management of acute and chronic pain in sickle cell disease.&quot; Glenview, IL: American Pain Society; 1999.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, &quot;Preparing for Pediatric Emergencies: Drugs to Consider,&quot; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henneberg SW, Hole P, Madsen de Haas I, et al, &ldquo;Epidural Morphine for Postoperative Pain Relief in Children,&rdquo; <i>Acta Anaesthesiol Scand</i>, 1993, 37(7):664-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/8249555/pubmed\" target=\"_blank\" id=\"8249555\">8249555</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hudak ML, Tan RC, AAP Committee on Drugs, et al, &quot;Neonatal Drug Withdrawal,&quot; <i>Pediatrics</i>, 2012, 129(2):e540-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/22291123/pubmed\" target=\"_blank\" id=\"22291123\">22291123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hunt A, Joel S, Dick G, et al, &ldquo;Population Pharmacokinetics of Oral Morphine and Its Glucuronides in Children Receiving Morphine as Immediate-Release Liquid or Sustained-Release Tablets for Cancer Pain,&rdquo; <i>J Pediatr</i>, 1999, 135(1):47-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/10393603/pubmed\" target=\"_blank\" id=\"10393603\">10393603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Infumorph 200 and Infumorph 500 (morphine sulfate injection) [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; September 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP), &ldquo;Beware of Basal Opioid Infusions With PCA Therapy,&rdquo; 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices (ISMP), &quot;Standard Concentrations of Neonatal Drug Infusions,&quot; <i>ISMP</i>, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jimenez N, Anderson GD, Shen DD, et al. Is ethnicity associated with morphine's side effects in children? Morphine pharmacokinetics, analgesic response, and side effects in children having tonsillectomy.<i> Paediatr Anaesth</i>. 2012;22(7):669-675.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/22486937 /pubmed\" target=\"_blank\" id=\"22486937 \">22486937 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kadian (morphine sulfate) [prescribing information]. Parsippany, NJ: Actavis Pharma Inc; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahan M, Wilson L, Mailis-Gagnon A, et al, &quot;Canadian Guideline For Safe and Effective Use of Opioids For Chronic Noncancer Pain: Clinical Summary For Family Physicians. Part 2: Special Populations,&quot; <i>Can Fam Physician</i>, 2011, 57(11):1269-76, e419-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/22084456/pubmed\" target=\"_blank\" id=\"22084456\">22084456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly LE, Sommer DD, Ramakrishna J, et al. Morphine or Ibuprofen for post-tonsillectomy analgesia: a randomized trial. <i>Pediatrics</i>. 2015;135(2):307-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/25624387 /pubmed\" target=\"_blank\" id=\"25624387 \">25624387 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier;2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar P, Denson SE, Mancuso TJ, et al, &quot;Premedication for Nonemergency Endotracheal Intubation in the Neonate,&quot; <i>Pediatrics</i>, 2010, 125(3):608-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/20176672/pubmed\" target=\"_blank\" id=\"20176672\">20176672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lugo RA, Kern SE. Clinical pharmacokinetics of morphine. <i>J Pain Palliat Care Pharmacother</i>. 2002;16(4):5-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/14635822 /pubmed\" target=\"_blank\" id=\"14635822 \">14635822 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lvovschi V, Aubrun F, Bonnet P, et al, &ldquo;Intravenous Morphine Titration to Treat Severe Pain in the ED,&rdquo; <i>Am J Emerg Med</i>, 2008, 26(6):676-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/18606320/pubmed\" target=\"_blank\" id=\"18606320\">18606320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Masood AR and Thomas SH, &quot;Systemic Absorption of Nebulized Morphine Compared With Oral Morphine in Healthy Subjects,&quot; <i>Br J Clin Pharmacol</i>, 1996, 41(3):250-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/8866928/pubmed\" target=\"_blank\" id=\"8866928\">8866928</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McRorie TI, Lynn AM, Nespeca MK, et al, &ldquo;The Maturation of Morphine Clearance and Metabolism,&rdquo; <i>Am J Dis Child</i>, 1992, 147(8):972-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/1636668/pubmed\" target=\"_blank\" id=\"1636668\">1636668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miser AW, Davis DM, Hughes CS, et al, &ldquo;Continuous Subcutaneous Infusion of Morphine in Children With Cancer,&rdquo; <i>Am J Dis Child</i>, 1983, 137(4):383-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/ 6187211 /pubmed\" target=\"_blank\" id=\" 6187211 \"> 6187211 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miser AW, Miser JS, and Clark BS, &ldquo;Continuous Intravenous Infusion of Morphine Sulfate for Control of Severe Pain in Children With Terminal Malignancy,&rdquo; <i>J Pediatr</i>, 1980, 96(5):930-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/7365606 /pubmed\" target=\"_blank\" id=\"7365606 \">7365606 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery A, Hale TW, and Academy of Breastfeeding Medicine, &quot;ABM Clinical Protocol #15: Analgesia and Anesthesia for the Breastfeeding Mother, Revised 2012,&quot; <i>Breastfeed Med</i>, 2012, 7(6):547-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morphabond (morphine sulfate) [prescribing information]. Valley Cottage, NY: Inspirion Delivery Technologies; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morphine sulfate oral solution [prescribing information]. Minneapolis, MN: Perrigo; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MS Contin (morphine sulfate) [prescribing information]. Stamford, CT: Purdue Pharma; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute (NHLBI). Evidence-based management of sickle cell disease: expert panel report, 2014. Bethesda, MD: National Institutes of Health; 2014. Available at <a href=\"http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines\" target=\"_blank\">http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines</a>. Accessed March 19, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Niscola P, Scaramucci L, Vischini G, et al. The use of major analgesics in patients with renal dysfunction.<i> Curr Drug Targets</i>. 2010;11(6):752-758.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/20041843 /pubmed\" target=\"_blank\" id=\"20041843 \">20041843 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olkkola KT, Hamunen K, and Maunuksela EL, &ldquo;Clinical Pharmacokinetics and Pharmacodynamics of Opioid Analgesics in Infants and Children,&rdquo; <i>Clin Pharmacokinet</i>, 1995, 28(5):385-404.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/7614777 /pubmed\" target=\"_blank\" id=\"7614777 \">7614777 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &quot;Standardizing I.V. Infusion Concentrations: National Survey Results,&quot; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&quot; 6th ed, Glenview, IL: American Pain Society, 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raghavendran S, Bagry H, Detheux G, Zhang X, Brouillette RT, Brown KA. An anesthetic management protocol to decrease respiratory complications after adenotonsillectomy in children with severe sleep apnea. <i>Anesth Analg</i>. 2010;110(4):1093-1101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/20142343 /pubmed\" target=\"_blank\" id=\"20142343 \">20142343 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rathmell JP, Lair TR, and Nauman B, &ldquo;The Role of Intrathecal Drugs in the Treatment of Acute Pain,&rdquo; <i>Anesth Analg</i>, 2005, 101(5 Suppl):30-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/16334491/pubmed\" target=\"_blank\" id=\"16334491\">16334491</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/23979084/pubmed\" target=\"_blank\" id=\"23979084\">23979084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sadhasivam S, Chidambaran V, Ngamprasertwong P, et al. Race and unequal burden of perioperative pain and opioid related adverse effects in children.<i> Pediatrics</i>. 2012;129(5):832-838.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/22529273 /pubmed\" target=\"_blank\" id=\"22529273 \">22529273 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shirk MB, Donahue KR, and Shirvani J, &quot;Unlabeled Uses of Nebulized Medications,&quot; <i>Am J Health Syst Pharm</i>, 2006, 63(18):1704-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/16960254/pubmed\" target=\"_blank\" id=\"16960254\">16960254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinclair-Pingel J, Grisso AG, Hargrove FR, Wright L. Implementation of standardized concentrations for continuous infusions using a computerized provider Oder Entry System [published correction appears in <i>Hosp Pharm</i>. 2007;42:84-85]. <i>Hosp Pharm</i>. 2006;41(11):1102-1106.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spigset O and Hagg S, &ldquo;Analgesics and Breast-feeding: Safety Considerations,&rdquo; <i>Paediatr Drugs</i>, 2000, 2(3):223-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/10937472/pubmed\" target=\"_blank\" id=\"10937472\">10937472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sultan P, Gutierrez MC, and Carvalho B, &ldquo;Neuraxial Morphine and Respiratory Depression: Finding the Right Balance,&rdquo; <i>Drugs</i>, 2011, 71(14):1807-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/21942973/pubmed\" target=\"_blank\" id=\"21942973\">21942973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suresh S, Birmingham PK, and Kozlowski RJ, &quot;Pediatric Pain Management,&quot; <i>Anesthesiol Clin</i>, 2012, 30(1):101-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/22405436/pubmed\" target=\"_blank\" id=\"22405436\">22405436</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zakowski MI, Ramanathan S, Turndorf H. A two-dose epidural morphine regimen in cesarean section patients: pharmacokinetic profile. <i>Acta Anaesthesiol Scand</i>. 1993;37(6):584-589.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/8213024/pubmed\" target=\"_blank\" id=\"8213024\">8213024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeltzer LK, Altman A, Cohen D, et al, &quot;American Academy of Pediatrics Report of the Subcommittee on the Management of Pain Associated With Procedures in Children With Cancer,&quot; <i>Pediatrics</i>, 1990, 86(5 Pt 2):826-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-pediatric-drug-information/abstract-text/2216645/pubmed\" target=\"_blank\" id=\"2216645\">2216645</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16024 Version 262.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50711535\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8775511\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8776636\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8776637\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10512349\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443893\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10512362\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8776907\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8776646\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F8776634\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F9845085\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10512363\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Neonatal\" href=\"#F14472939\" class=\"outlineLink\">Usual Infusion Concentrations: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472938\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8776743\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10512350\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8775520\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8776724\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8776704\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8776705\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26535459\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8776734\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8776735\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F8776739\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8776700\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10512364\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8776768\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8776772\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10512367\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F45042893\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8776910\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961991\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16024|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">Morphine: Drug information</a></li><li><a href=\"topic.htm?path=morphine-patient-drug-information\" class=\"drug drug_patient\">Morphine: Patient drug information \t</a></li></ul></div></div>","javascript":null}